Our mouse lung-mesenchymal Tsc2-null model will be useful in understanding the evolution of mTORC1-driven lung pathologies and will serve as a preclinical model for identifying and testing therapeutic targets, not only for LAM but also potentially for other lung diseases with activated mTORC1. This evidence concerns the gene TSC2 and lung disorder.